Futures
Access hundreds of perpetual contracts
CFD
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
CFD
Stock CFD Derivatives
US Stocks
Access real US stocks and ETFs
HK Stocks
Trade quality Hong Kong-listed stocks
Korean Stocks
SK Hynix
Real Korean stocks and top assets
Stock Futures
High leverage, 24/7 trading
Tokenized Stocks
Backed by real stock assets
IPO Access
Unlock full access to global stock IPOs
GUSD
3.8%
Mint GUSD for Treasury RWA yields
Stocks Activities
Trade Popular Stocks and Unlock Generous Airdrops
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
IPO Access
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Promotions
AI
Gate AI
Your all-in-one conversational AI partner
Gate AI Bot
Use Gate AI directly in your social App
GateClaw
Gate Blue Lobster, ready to go
Gate for AI Agent
AI infrastructure, Gate MCP, Skills, and CLI
Gate Skills Hub
10K+ Skills
From office tasks to trading, the all-in-one skill hub makes AI even more useful.
China Antibody: plans to sell properties and facilities in Suzhou Industrial Park for 280 million yuan, expected loss of 56.34 million yuan
Recently, China Antibody issued an announcement stating that its wholly owned subsidiary, Xinglian Pharmaceutical (Suzhou), entered into a sale and purchase agreement with Suzhou Yigong Buyuan Biopharmaceutical Co., Ltd. (the buyer) and Suzhou Yilian Biopharmaceutical Co., Ltd. (the guarantor). The company plans to sell industrial land and above-ground buildings located in the Suzhou Industrial Park for RMB 280 million. The total land area is approximately 43.2k square meters, and the total gross floor area is approximately 71.3k square meters.
The announcement said that the target assets’ consolidated book net value as of June 30, 2026 is approximately RMB 336 million. The company expects to record a one-time non-operating loss of approximately RMB 56.34 million. The actual loss will be subject to audit, and the buyer is a wholly owned subsidiary of the guarantor.
(China Antibody announcement)